About this Journal Submit a Manuscript Table of Contents
Journal of Drug Delivery
Volume 2012 (2012), Article ID 173465, 9 pages
http://dx.doi.org/10.1155/2012/173465
Review Article

Reversible Masking Using Low-Molecular-Weight Neutral Lipids to Achieve Optimal-Targeted Delivery

1Delivery Systems, Gradalis Inc., 2545 Golden Bear Drive, Suite 110, Carrollton, TX 75006-2317, USA
2Mary Crowley Cancer Research Centers, 1700 Pacific Avenue, Suite 1100, Dallas, TX 75201, USA

Received 14 November 2011; Revised 9 February 2012; Accepted 27 February 2012

Academic Editor: Fabiana Quaglia

Copyright © 2012 Nancy Smyth Templeton and Neil Senzer. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. N. S. Templeton, D. D. Lasic, P. M. Frederik, H. H. Strey, D. D. Roberts, and G. N. Pavlakis, “Improved DNA: liposome complexes for increased systemic delivery and gene expression,” Nature Biotechnology, vol. 15, no. 7, pp. 647–652, 1997. View at Scopus
  2. N. S. Templeton, “Myths concerning the use of cationic liposomes in vivo,” Expert Opinion on Biological Therapy, vol. 3, no. 1, pp. 57–69, 2003. View at Publisher · View at Google Scholar · View at Scopus
  3. N. S. Templeton, “Nonviral delivery for genomic therapy of cancer,” World Journal of Surgery, vol. 33, no. 4, pp. 685–697, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. N. S. Templeton, Ed., Liposome Gene Transfection, Wiley-VCH Verlag GmbH, Weinheim, Germany, 2008.
  5. N. S. Templeton, “Liposomal delivery of nucleic acids in vivo,” DNA and Cell Biology, vol. 21, no. 12, pp. 857–867, 2002. View at Publisher · View at Google Scholar · View at Scopus
  6. C. Lu, et al., “Systemic gene therapy with tumor suppressor TUSC2/FUS1 nanoparticles for recurrent/metastatic lung cancer,” in Proceedings of the Annual Meeting of the American Association of Cancer Research (AACR), Orlando, Fla, USA, 2011.
  7. G. Nemunaitis, C. M. Jay , P. B. Maples, et al., “Hereditary inclusion body myopathy: single patient response to intravenous dosing of GNE gene lipoplex,” Human Gene Therapy, vol. 22, no. 11, pp. 1331–1341, 2011.
  8. G. Nemunaitis, P. B. Maples, C. Jay et al., “Hereditary inclusion body myopathy: single patient response to GNE gene Lipoplex therapy,” Journal of Gene Medicine, vol. 12, no. 5, pp. 403–412, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. Q. Shi, A. T. Nguyen, Y. Angell et al., “A combinatorial approach for targeted delivery using small molecules and reversible masking to bypass nonspecific uptake in vivo,” Gene Therapy, vol. 17, no. 9, pp. 1085–1097, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. S. M. Grosse, A. D. Tagalakis, M. F. M. Mustapa et al., “Tumor-specific gene transfer with receptor-mediated nanocomplexes modified by polyethylene glycol shielding and endosomally cleavable lipid and peptide linkers,” FASEB Journal, vol. 24, no. 7, pp. 2301–2313, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. A. D. Tagalakis, S. M. Grosse, Q. H. Meng et al., “Integrin-targeted nanocomplexes for tumour specific delivery and therapy by systemic administration,” Biomaterials, vol. 32, no. 5, pp. 1370–1376, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. H. Hatakeyama, H. Akita, and H. Harashima, “A multifunctional envelope type nano device (MEND) for gene delivery to tumours based on the EPR effect: a strategy for overcoming the PEG dilemma,” Advanced Drug Delivery Reviews, vol. 63, no. 3, pp. 152–160, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. H. Hatakeyama, H. Akita, E. Ito et al., “Systemic delivery of siRNA to tumors using a lipid nanoparticle containing a tumor-specific cleavable PEG-lipid,” Biomaterials, vol. 32, no. 18, pp. 4306–4316, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. K. M. McNeeley, E. Karathanasis, A. V. Annapragada, and R. V. Bellamkonda, “Masking and triggered unmasking of targeting ligands on nanocarriers to improve drug delivery to brain tumors,” Biomaterials, vol. 30, no. 23-24, pp. 3986–3995, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. T Thambi, H. Y. Yoon, K. Kim, et al., “Bioreducible block copolymers based on poly(ethylene glycol) and poly(γ-benzyl L-glutamate) for intracellular delivery of camptothecin,” Bioconjugate Chemistry, vol. 22, no. 10, pp. 1924–1931, 2011.
  16. R. Kuai, W. Yuan, W. Li, et al., “Targeted delivery of cargoes into a murine solid tumor by a cell-penetrating peptide and cleavable poly(ethylene glycol) comodified liposomal delivery system via systemic administration,” Molecular Pharmacology, vol. 8, no. 6, pp. 2151–2161, 2011.
  17. R. Kuai, W. Yuan, Y. Qin et al., “Efficient delivery of payload into tumor cells in a controlled manner by TAT and thiolytic cleavable PEG Co-modified liposomes,” Molecular Pharmaceutics, vol. 7, no. 5, pp. 1816–1826, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. R. Ramesh, T. Saeki, N. Smyth Templeton et al., “Successful treatment of primary and disseminated human lung cancers by systemic delivery of tumor suppressor genes using an improved liposome vector,” Molecular Therapy, vol. 3, no. 3, pp. 337–350, 2001. View at Publisher · View at Google Scholar · View at Scopus
  19. H. Y. Shi, R. Liang, N. S. Templeton, and M. Zhang, “Inhibition of breast tumor progression by systemic delivery of the maspin gene in a syngeneic tumor model,” Molecular Therapy, vol. 5, no. 6, pp. 755–761, 2002. View at Publisher · View at Google Scholar · View at Scopus
  20. T. A. Tirone, S. P. Fagan, N. S. Templeton, X. Wang, and F. C. Brunicardi, “Insulinoma-induced hypoglycemic death in mice is prevented with beta cell-specific gene therapy,” Annals of Surgery, vol. 233, no. 5, pp. 603–611, 2001. View at Publisher · View at Google Scholar · View at Scopus
  21. S. H. Liu, N. Smyth-Templeton, A. R. Davis et al., “Multiple treatment cycles of liposome-encapsulated adenoviral RIP-TK gene therapy effectively ablate human pancreatic cancer cells in SCID mice,” Surgery, vol. 149, no. 4, pp. 484–495, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. S. Liu, N. Ballian, N. S. Belaguli et al., “PDX-1 acts as a potential molecular target for treatment of human pancreatic cancer,” Pancreas, vol. 37, no. 2, pp. 210–220, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. W. H. Pan, P. Xin, J. D. Morrey, and G. A. Clawson, “A self-processing ribozyme cassette: utility against human papillomavirus 11 E6/E7 mRNA and hepatitis B virus,” Molecular Therapy, vol. 9, no. 4, pp. 596–606, 2004. View at Publisher · View at Google Scholar · View at Scopus
  24. B. Sternberg, “Morphology of cationic liposome/DNA complexes in relation to their chemical composition,” Journal of Liposome Research, vol. 6, no. 3, pp. 515–533, 1996. View at Scopus
  25. P. L. Felgner, T. R. Gadek, M. Holm et al., “Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure.,” Proceedings of the National Academy of Sciences of the United States of America, vol. 84, no. 21, pp. 7413–7417, 1987. View at Scopus
  26. J. H. Felgner, R. Kumar, C. N. Sridhar et al., “Enhanced gene delivery and mechanism studies with a novel series of cationic lipid formulations,” The Journal of Biological Chemistry, vol. 269, no. 4, pp. 2550–2561, 1994. View at Scopus
  27. J. Senior, C. Delgado, D. Fisher, C. Tilcock, and G. Gregoriadis, “Influence of surface hydrophilicity of liposomes on their interaction with plasma protein and clearance from the circulation: studies with poly(ethylene glycol)-coated vesicles,” Biochimica et Biophysica Acta, vol. 1062, no. 1, pp. 77–82, 1991. View at Publisher · View at Google Scholar · View at Scopus
  28. D. Papahadjopoulos, T. M. Allen, A. Gabizon et al., “Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy,” Proceedings of the National Academy of Sciences of the United States of America, vol. 88, no. 24, pp. 11460–11464, 1991. View at Scopus
  29. A. Gabizon, R. Catane, B. Uziely et al., “Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes,” Cancer Research, vol. 54, no. 4, pp. 987–992, 1994. View at Scopus
  30. K. B. Gordon, A. Tajuddin, and J. Guitart, “Hand-foot syndrome associated with liposome-encapsulated doxorubicin therapy,” Cancer, vol. 75, pp. 2169–2173, 1995.
  31. B. Uziely, S. Jeffers, R. Isacson et al., “Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies,” Journal of Clinical Oncology, vol. 13, no. 7, pp. 1777–1785, 1995. View at Scopus
  32. Y. Sakurai, H. Hatakeyama, H. Akita et al., “Efficient short interference rna delivery to tumor cells using a combination of octaarginine, gala and tumor-specific, cleavable polyethylene glycol system,” Biological and Pharmaceutical Bulletin, vol. 32, no. 5, pp. 928–932, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. J. Gustafsson, G. Arvidson, G. Karlsson, and M. Almgren, “Complexes between cationic liposomes and DNA visualized by cryo-TEM,” Biochimica et Biophysica Acta, vol. 1235, no. 2, pp. 305–312, 1995. View at Publisher · View at Google Scholar · View at Scopus
  34. N. S. Templeton and D. D. Lasic, “New directions in liposome gene delivery,” Applied Biochemistry and Biotechnology—Part B, vol. 11, no. 2, pp. 175–180, 1999. View at Scopus
  35. R. K. Jain, “Barriers to drug delivery in solid tumors,” Scientific American, vol. 271, no. 1, pp. 58–65, 1994. View at Scopus
  36. R. K. Jain, “Haemodynamic and transport barriers to the treatment of solid tumours,” International Journal of Radiation Biology, vol. 60, no. 1-2, pp. 85–100, 1991. View at Scopus
  37. R. K. Jain, “Transport of molecules, particles, and cells in solid tumors,” Annual Review of Biomedical Engineering, no. 1, pp. 241–263, 1999. View at Scopus
  38. N. S. Templeton, et al., “Non-viral vectors for the treatment of disease,” in Proceedings of the Keystone Symposia on Molecular and Cellular Biology of Gene Therapy, Salt Lake City, Utah, 1999.
  39. J. Repits, J. Sterjovski, D. Badia-Martinez et al., “Primary HIV-1 R5 isolates from end-stage disease display enhanced viral fitness in parallel with increased gp120 net charge,” Virology, vol. 379, no. 1, pp. 125–134, 2008. View at Publisher · View at Google Scholar · View at Scopus
  40. T. Cilliers, J. Nhlapo, M. Coetzer et al., “The CCR5 and CXCR4 coreceptors are both used by human immunodeficiency virus type 1 primary isolates from subtype C,” Journal of Virology, vol. 77, no. 7, pp. 4449–4456, 2003. View at Publisher · View at Google Scholar · View at Scopus
  41. E. Lee, R. A. Hall, and M. Lobigs, “Common E protein determinants for attenuation of glycosaminoglycan-binding variants of Japanese encephalitis and West Nile viruses,” Journal of Virology, vol. 78, no. 15, pp. 8271–8280, 2004. View at Publisher · View at Google Scholar · View at Scopus
  42. L. Markoff, B. Falgout, and A. Chang, “A conserved internal hydrophobic domain mediates the stable membrane integration of the dengue virus capsid protein,” Virology, vol. 233, no. 1, pp. 105–117, 1997. View at Publisher · View at Google Scholar · View at Scopus
  43. J. D. Reeves and T. F. Schulz, “The CD4-independent tropism of human immunodeficiency virus type 2 involves several regions of the envelope protein and correlates with a reduced activation threshold for envelope-mediated fusion,” Journal of Virology, vol. 71, no. 2, pp. 1453–1465, 1997. View at Scopus
  44. A. C. Andeweg, P. H. M. Boers, A. D. M. E. Osterhaus, and M. L. Bosch, “Impact of natural sequence variation in the V2 region of the envelope protein of human immunodeficiency virus type 1 on syncytium induction: a mutational analysis,” Journal of General Virology, vol. 76, no. 8, pp. 1901–1907, 1995. View at Scopus
  45. J. P. Behr, B. Demeneix, J. P. Loeffler, and J. Perez-Mutul, “Efficient gene transfer into mammalian primary endocrine cells with lipopolyamine-coated DNA,” Proceedings of the National Academy of Sciences of the United States of America, vol. 86, no. 18, pp. 6982–6986, 1989. View at Scopus
  46. P. L. Felgner and G. M. Ringold, “Cationic liposome-mediated transfection,” Nature, vol. 337, no. 6205, pp. 387–388, 1989. View at Scopus
  47. P. Pinnaduwage and L. Huang, “The role of protein-linked oligosaccharide in the bilayer stabilization activity of glycophorin A for dioleoylphosphatidylethanolamine liposomes,” Biochimica et Biophysica Acta, vol. 986, no. 1, pp. 106–114, 1989. View at Scopus
  48. R. Leventis and J. R. Silvius, “Interactions of mammalian cells with lipid dispersions containing novel metabolizable cationic amphiphiles,” Biochimica et Biophysica Acta, vol. 1023, no. 1, pp. 124–132, 1990. View at Publisher · View at Google Scholar · View at Scopus
  49. J. K. Rose, L. Buonocore, and M. A. Whitt, “A new cationic liposome reagent mediating nearly quantitative transfection of animal cells,” BioTechniques, vol. 10, no. 4, pp. 520–525, 1991. View at Scopus
  50. J. P. Loeffler and J. P. Behr, “Gene transfer into primary and established mammalian cell lines with lipopolyamine-coated DNA,” Methods in Enzymology, vol. 217, pp. 599–642, 1993. View at Scopus
  51. J. D. Hood, M. Bednarski, R. Frausto et al., “Tumor regression by targeted gene delivery to the neovasculature,” Science, vol. 296, no. 5577, pp. 2404–2407, 2002. View at Publisher · View at Google Scholar · View at Scopus